Amandeep Salhotra, M.D. | City of Hope

Dr. Amandeep Salhotra

Claim this profile

City of Hope Medical Center

Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
12 reported clinical trials
21 drugs studied

Area of expertise

1

Acute Myelogenous Leukemia

Amandeep Salhotra has run 7 trials for Acute Myelogenous Leukemia. Some of their research focus areas include:

IDH positive
HLA-A positive
HLA-A negative
2

Acute Myeloid Leukemia

Amandeep Salhotra has run 7 trials for Acute Myeloid Leukemia. Some of their research focus areas include:

IDH positive
TP53 negative
PML-RARA negative

Affiliated Hospitals

Image of trial facility.

City Of Hope Medical Center

Image of trial facility.

City Of Hope Comprehensive Cancer Center

Clinical Trials Amandeep Salhotra is currently running

Image of trial facility.

Tabelecleucel

for Post-Transplant Cancer

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.

Recruiting

2 awards

Phase 3

12 criteria

Image of trial facility.

Orca-T and Radiation Therapy

for Leukemia

This phase I trial tests the side effects and best dose of total marrow lymphoid irradiation along with chemotherapy, with fludarabine and melphalan, with or without thiotepa, in combination with Orca-T cells for patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or myelodysplastic syndrome (MDS). Total marrow and lymphoid irradiation is a targeted form of total body irradiation that uses intensity-modulated radiation therapy to target marrow, lymph node chains, and the spleen. It is designed to reduce radiation-associated side effects and maximize the radiation therapeutic effect. Giving chemotherapy with medications such as thiotepa, fludarabine, and melphalan before a treatment with stem cells helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. Orca-T cells take cells from a donor and remove some of the T cells and replace them with partially engineered T cells in order to induce better tolerance in patients. Giving total marrow and lymphoid irradiation and chemotherapy followed by Orca -T cells may be an effective treatment for patients with AML, ALL or MDS.

Recruiting

1 award

Phase 1

More about Amandeep Salhotra

Clinical Trial Related

8 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 5 Active Clinical Trials

Treatments Amandeep Salhotra has experience with

  • Olutasidenib
  • Leflunomide
  • Enasidenib Mesylate
  • CD6-CAR Tregs
  • Fludarabine
  • Melphalan

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Amandeep Salhotra specialize in?

Is Amandeep Salhotra currently recruiting for clinical trials?

Are there any treatments that Amandeep Salhotra has studied deeply?

What is the best way to schedule an appointment with Amandeep Salhotra?

What is the office address of Amandeep Salhotra?

Is there any support for travel costs?